Cargando…

Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection

New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stalter, Randy M, Baeten, Jared M, Donnell, Deborah, Spinelli, Matthew A, Glidden, David V, Rodrigues, Warren C, Wang, Guohong, Vincent, Michael, Mugo, Nelly, Mujugira, Andrew, Marzinke, Mark, Hendrix, Craig, Gandhi, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850546/ https://www.ncbi.nlm.nih.gov/pubmed/33527128 http://dx.doi.org/10.1093/cid/ciaa785

Ejemplares similares

Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence
por: Gandhi, Monica, et al.
Publicado: (2018)

Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial
por: Drain, Paul, et al.
Publicado: (2020)

HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention
por: Donnell, Deborah, et al.
Publicado: (2014)

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
por: Johnson, Kelly A, et al.
Publicado: (2021)

Sexual Behaviors After PrEP Discontinuation Among HIV Serodiscordant Couples in Kenya and Uganda
por: Stalter, Randy, et al.
Publicado: (2020)

Hypo-osmolar rectal douche tenofovir formulation prevents simian/human immunodeficiency virus acquisition in macaques
por: Xiao, Peng, et al.
Publicado: (2022)

Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
por: Tanaudommongkon, Asama, et al.
Publicado: (2022)

Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
por: Baeten, Jared M., et al.
Publicado: (2016)

The Effect of Human Immunodeficiency Virus Prevention and Reproductive Health Text Messages on Human Immunodeficiency Virus Testing Among Young Women in Rural Kenya: A Pilot Study
por: Njuguna, Njambi, et al.
Publicado: (2016)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women
por: Pyra, Maria, et al.
Publicado: (2019)

Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
por: Scott, Rachel K., et al.
Publicado: (2023)

Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial( )
por: Mugo, Nelly R, et al.
Publicado: (2021)

Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults
por: Nickolas, Thomas L, et al.
Publicado: (2019)

High Medication Adherence During Periconception Periods Among HIV-1–Uninfected Women Participating in a Clinical Trial of Antiretroviral Pre-exposure Prophylaxis
por: Matthews, Lynn T., et al.
Publicado: (2014)

Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption
por: Mugwanya, Kenneth K., et al.
Publicado: (2016)

Adherence determination using urine-tenofovir point-of-care testing and pharmacy refill records: A cross-sectional study
por: Herbertson, Ebiere C., et al.
Publicado: (2023)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring
por: Niu, Xin, et al.
Publicado: (2022)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial
por: Glidden, David V, et al.
Publicado: (2021)

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa
por: Heffron, Renee, et al.
Publicado: (2018)

Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study
por: Roberts, Sarah T., et al.
Publicado: (2016)

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study
por: Cressey, Tim R., et al.
Publicado: (2017)

Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya
por: Mugo, Nelly R., et al.
Publicado: (2023)

Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
por: Seo, Jun-Won, et al.
Publicado: (2020)

Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study)
por: Hofmeyr, G. Justus, et al.
Publicado: (2018)

A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy
por: Beigi, Richard H, et al.
Publicado: (2016)

Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men
por: Shieh, Eugenie, et al.
Publicado: (2019)

FAME‐04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir
por: Bunge, Katherine E, et al.
Publicado: (2018)

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2020)

Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring
por: Thurman, Andrea R., et al.
Publicado: (2022)

Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa
por: Matthews, Lynn T, et al.
Publicado: (2019)

Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner
por: Lade, Julie M., et al.
Publicado: (2015)

Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women
por: Kourtis, Athena P., et al.
Publicado: (2017)

HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya
por: Ortblad, Katrina F., et al.
Publicado: (2019)

PrEP as a Lifestyle and Investment for Adolescent Girls and Young Women in Sub-Saharan Africa
por: Haberer, Jessica E., et al.
Publicado: (2019)

Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2022)

Risk Factors for HSV-2 Infection among Sexual Partners of HSV-2/HIV-1 Co-Infected Persons
por: Mujugira, Andrew, et al.
Publicado: (2011)

No Evidence of Sexual Risk Compensation Following PrEP Initiation Among Heterosexual HIV Serodiscordant Couples in Kenya and Uganda
por: Ortblad, Katrina F., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rd84frskvh1jq5qu2ea81lbep5